Janssen Biotech Inc.

09/27/2021 | Press release | Distributed by Public on 09/27/2021 06:52

New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots[...]